Duchenne Muscular Dystrophy is at the forefront of the rare disease space. For more information about the muscoloskeletal disorder, read Rare Disease Report.
Capricor Receives Rare Pediatric Disease Designation for DMD Drug
If their DMD drug gets approved, Capricor Therapeutics would receive a Priority Review Voucher that is worth millions of dollars.
The FDA has granted Orphan Drug Designation to Mallinckrodt for their potential Duchenne muscular dystrophy (DMD) treatment, MNK-1411.
On Friday afternoon at the PPMD Patient Connect Meeting, Catabasis, Mitobridge, and Fibrogen provided clinical data updates.
DMD updates from Pfizer, BMS, Capricor,Reveragen, Santhera, Italfarmaco, Akashi at PPMD's patient conference.
A who's who from the pharma industry will be at the DMD conference to share clinical trial updates
On June 20, the Massachusetts-based FSH society is asking everyone to observe the inaugural World FSHD Day to raise awareness for the rare disorder.
Tri4Jett is comprised of approximately 25 triathletes who will be working with Jett McSherry to make sure he crosses the finish line.
University of Southern California (USC) start-up RASRx hopes to develop a drug to treat Duchenne muscular dystrophy (DMD). CureDuchenne Ventures is investing in the drug.
Since 2003, CureDuchenne has dedicated itself to funding research, raising awareness and improving patient care for Duchenne muscular dystrophy (DMD).
Domagrozumab is a monoclonal antibody directed towards myostatin, a protein in muscles that helps control muscle growth.
$vacMongoViewPlus$ $vAR$